Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and ...

The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor ...

Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer ...

Indeed, germline TP53 and EGFR mutations are associated with early-onset lung tumors. 76, 77 However, rare variants such as BRCA K3326* (OR, 2.1 for small cell lung cancer and OR, 1.7 for squamous ...

A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

Small cell lung cancer is the more aggressive, typically spreading beyond the lungs before diagnosis. About 80-85% of lung ...

The U.S. Food and Drug Administration had approved Ibtrozi (taletrectinib) for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The efficacy of the ...

SCLC incidence in the US is projected to decline significantly through 2050, continuing a trend from 2000 to 2021. The study ...

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

This can disrupt the cancer cell’s life cycle and may lead to cell death. The FDA granted accelerated approval to Zepzelca in June 2020 for those whose metastatic small cell lung cancer has progressed ...

When non-small cell lung cancer (NSCLC) spreads beyond the lungs, it often metastasizes to the bones. Estimates suggest 20 to 30 percent of people with NSCLC have bone metastases at the time of ...